Jeffrey W. Albers
Known title: DirectorCIK: 0001638474
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Raymond James initiates coverage on Kymera with Outperform rating. Raymond James has started covering Kymera Therapeutics, assigning an Outperform rating and a price target of $140. This new analyst note adds to the current consensus, which has an average target of $139.35 from 23 analysts. Recent discussions also question whether the company's pipeline is over-hyped or developing into a major therapeutic success.
Transaction History
| SYRE | ▼ Sell | Open Market | 10,000 | $1.0M | 8/7/2026 | View on chart |
| SYRE | ▲ Buy | Option Exercise | 5,000 | $52K | 8/7/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 5,000 | $522K | 8/7/2026 | View on chart |
| SYRE | ▼ Sell | Open Market | 8,000 | $835K | 8/7/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 2,252 | $203K | 12/8/2025 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 5,000 | $71K | 12/8/2025 | View on chart |
| KYMR | ▼ Sell | Open Market | 2,748 | $245K | 12/8/2025 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 5,000 | $52K | 10/13/2025 | View on chart |
| KYMR | ▼ Sell | Open Market | 5,000 | $296K | 10/13/2025 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 6,349 | $66K | 6/3/2025 | View on chart |
| KYMR | ▼ Sell | Open Market | 6,349 | $311K | 6/3/2025 | View on chart |
| SYRE | ▼ Sell | Open Market | 6,700 | $246K | 11/6/2024 | View on chart |
| SYRE | ▼ Sell | Open Market | 300 | $11K | 10/25/2024 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 5,000 | $52K | 8/26/2024 | View on chart |
| KYMR | ▼ Sell | Open Market | 5,000 | $246K | 8/26/2024 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 4,385 | $45K | 2/21/2024 | View on chart |
| KYMR | ▼ Sell | Open Market | 4,385 | $171K | 2/21/2024 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 615 | $6K | 2/20/2024 | View on chart |
| KYMR | ▼ Sell | Open Market | 615 | $24K | 2/20/2024 | View on chart |
| KYMR | ▲ Buy | Option Exercise | 10,000 | $103K | 1/23/2024 | View on chart |
| KYMR | ▼ Sell | Open Market | 10,000 | $300K | 1/23/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Spyre Therapeutics Launches $350M Public Offering, Stock Drops
Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.
Spyre Therapeutics Launches $350M Public Offering, Stock Drops. Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.